Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy A Meta-analysis

被引:76
|
作者
Al-Khatib, Sana M. [1 ]
Fonarow, Gregg C. [2 ]
Joglar, Jose A. [3 ]
Inoue, Lurdes Y. T. [4 ]
Mark, Daniel B. [1 ]
Lee, Kerry L. [5 ]
Kadish, Alan [6 ]
Bardy, Gust [7 ]
Sanders, Gillian D. [8 ]
机构
[1] Duke Univ, Med Ctr, Div Cardiol, Duke Clin Res Inst, Durham, NC 27710 USA
[2] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA
[3] Univ Texas Southwestern, Div Cardiol, Dallas, TX USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Biostat & Bioinformat, Durham, NC USA
[6] Northwestem Mem Hosp, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
[7] Univ Washington, Div Cardiol, Seattle, WA 98195 USA
[8] Duke Univ, Med Ctr, Dept Clin Pharmacol, Duke Clin Res Inst, Durham, NC USA
关键词
SYSTOLIC HEART-FAILURE; DILATED CARDIOMYOPATHY;
D O I
10.1001/jamacardio.2017.0630
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. OBJECTIVE To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. DATA SOURCES PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. STUDY SELECTION Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1 met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. DATA EXTRACTION AND SYNTHESIS The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed-and random-effects models. MAIN OUTCOMES AND MEASURES The primary end pointwas all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. RESULTS Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P=.008; P=.87 for heterogeneity). CONCLUSIONS AND RELEVANCE Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.
引用
收藏
页码:685 / 688
页数:4
相关论文
共 50 条
  • [11] Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy - A meta-analysis of randomized controlled trials
    Desai, AS
    Fang, JC
    Maisel, WH
    Baughman, KL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23): : 2874 - 2879
  • [12] Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy
    Voskoboinik, Aleksandr
    Bloom, Jason
    Taylor, Andrew
    Mariani, Justin
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2016, 39 (09): : 992 - 998
  • [13] Implantable Cardioverter-Defibrillators in Nonischemic Cardiomyopathy
    Berger, Rebecca E.
    Ellenbogen, Kenneth A.
    Stevenson, William G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (23): : 2290 - 2292
  • [14] Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathy Reply
    Al-Khatib, Sana M.
    Fonarow, Gregg C.
    Sanders, Gillian D.
    JAMA CARDIOLOGY, 2017, 2 (11) : 1283 - 1284
  • [15] Implantable Cardioverter Defibrillators for Primary Prevention in Patients With Ischemic and Non Ischemic Cardiomyopathy: A Meta-Analysis of 15 Randomized Controlled Trial
    Jaiswal, Vikash
    Jaiswal, Akash
    Taha, Amira Mohamed
    Kalra, Kriti
    Nasir, Yusra
    CIRCULATION, 2023, 148
  • [16] Implantable cardioverter defibrillator in nonischemic cardiomyopathy: A systematic review and meta-analysis
    Khan, Safi U.
    Ghimire, Subash
    Talluri, Swapna
    Rahman, Hammad
    Khan, Muhammad U.
    Nasir, Fahad
    Kaluski, Edo
    JOURNAL OF ARRHYTHMIA, 2018, 34 (01) : 4 - 10
  • [17] Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy An Updated Meta-Analysis
    Golwala, Harsh
    Bajaj, Navkaranbir Singh
    Arora, Garima
    Arora, Pankaj
    CIRCULATION, 2017, 135 (02) : 201 - 203
  • [18] PREDICTIVE VALUE OF FRAGMENTED QRS IN NONISCHEMIC DILATED CARDIOMYOPATHY PATIENTS WHO RECEIVE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS FOR PRIMARY PREVENTION
    Demiri, E.
    Kabakci, G.
    Taher, A.
    Ulgen, A.
    Karakulak, U.
    Kaya, E. B.
    Sahiner, L.
    Yorgun, H.
    Aytemir, K.
    Oto, A.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 163 : S37 - S37
  • [19] Cardiovascular Outcomes With Use of Primary Prevention Implantable Cardioverter Defibrillators in Patients With Non-Ischemic Cardiomyopathy: A Meta-Analysis and Meta-Regression Analysis
    Lone, Ahmad Naeem
    Ghosh, Priyanka
    Zaidi, Ali
    Sporn, Daniel
    Deshmukh, Pramod
    CIRCULATION, 2022, 146
  • [20] Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy
    Vrijraj S. Rathod
    Martin Stiles
    Current Treatment Options in Cardiovascular Medicine, 2022, 24 : 123 - 136